Teleflex (NYSE:TFX) Releases Earnings Results, Beats Expectations By $0.18 EPS

Teleflex (NYSE:TFX) announced its earnings results on Thursday. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.21 by $0.18, Briefing.com reports. The company had revenue of $548.30 million during the quarter, compared to analysts’ expectations of $536.91 million. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. Teleflex’s quarterly revenue was up 32.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.44 earnings per share. Teleflex updated its FY 2026 guidance to 6.250-6.550 EPS.

Here are the key takeaways from Teleflex’s conference call:

• Teleflex says its strategic divestitures remain on track to close in H2 2026 (OEM HSR period expired and OEM expected to close in Q3), and it intends to use roughly $1.8 billion of net proceeds to fund up to a $1 billion share repurchase program and repay about $800 million of debt, with opportunistic buybacks to begin in Q2.
• First quarter continuing-operations revenue was $548.3M (GAAP +32.3%, pro forma adjusted constant currency +5.1%) while adjusted EPS was $1.39 (down 3.5% YoY), with adjusted operating margin at 18.1% reflecting near-term margin pressure from tariffs, logistics, the vascular intervention acquisition and remediation charges.
• Management disclosed two third‑party supplier recalls affecting components in some vascular interventional kits, has taken remediation provisions in Q1, and warns the recalls may cause elevated backorders in Q2 even though they do not currently expect a material full‑year revenue impact.
• 2026 guidance remains pro forma revenue growth of 4.5%–5.5% and adjusted EPS of $6.25–$6.55, but assumes about $90 million of stranded costs and a fully burdened operating margin near 19% (management estimates a ~23% steady‑state margin once TSAs/MSAs and separation impacts are realized, with meaningful EPS improvement expected in 2027).
• R&D momentum: the Freesolve drug‑eluting resorbable magnesium scaffold program (BIOMAG‑II) is enrolling ahead of plan with a late‑2027 EU readout expected and a U.S. pivotal (BIOMAG‑III) planned to start in 2026, representing a potential long‑term growth driver.

Teleflex Price Performance

TFX traded up $1.49 on Friday, hitting $133.17. 947,217 shares of the stock were exchanged, compared to its average volume of 1,030,809. Teleflex has a 12 month low of $100.18 and a 12 month high of $139.67. The business has a 50-day moving average of $119.44 and a two-hundred day moving average of $116.73. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.55 and a quick ratio of 2.01. The firm has a market capitalization of $5.89 billion, a price-to-earnings ratio of -5.84, a PEG ratio of 0.96 and a beta of 0.82.

Teleflex Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 31st. Investors of record on Friday, March 6th were given a dividend of $0.34 per share. The ex-dividend date of this dividend was Friday, March 6th. This represents a $1.36 annualized dividend and a yield of 1.0%. Teleflex’s dividend payout ratio is currently -5.96%.

Institutional Investors Weigh In On Teleflex

Institutional investors and hedge funds have recently bought and sold shares of the company. UMB Bank n.a. lifted its position in Teleflex by 57.1% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock worth $38,000 after purchasing an additional 113 shares during the period. Kestra Advisory Services LLC bought a new stake in Teleflex during the fourth quarter worth about $45,000. Danske Bank A S bought a new stake in Teleflex during the third quarter worth about $54,000. State of Wyoming bought a new stake in Teleflex during the second quarter worth about $111,000. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Teleflex by 108.1% in the second quarter. EverSource Wealth Advisors LLC now owns 1,003 shares of the medical technology company’s stock worth $119,000 after acquiring an additional 521 shares during the last quarter. Institutional investors own 95.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Mizuho set a $140.00 target price on shares of Teleflex in a research report on Friday. Zacks Research raised shares of Teleflex from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. Wells Fargo & Company boosted their target price on shares of Teleflex from $130.00 to $138.00 and gave the company an “equal weight” rating in a research report on Friday. Weiss Ratings reissued a “sell (d)” rating on shares of Teleflex in a research report on Friday, March 27th. Finally, Wall Street Zen cut shares of Teleflex from a “hold” rating to a “sell” rating in a research report on Saturday. Three analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Teleflex presently has an average rating of “Hold” and an average price target of $142.86.

Key Teleflex News

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Teleflex beat Q1 estimates, reporting adjusted EPS of $1.39 versus $1.21 expected and revenue of $548.3 million versus $536.9 million expected, which signals solid execution in the quarter. Article Title
• Positive Sentiment: The company maintained its full-year 2026 outlook and announced plans for a buyback, which can support investor confidence and share price performance. Article Title
• Positive Sentiment: Wells Fargo raised its price target on TFX from $130 to $138, implying modest upside from current levels and suggesting improved analyst sentiment. Article Title
• Neutral Sentiment: Management’s earnings call commentary was described as balanced, with growth offset by margin strain, indicating the business is still navigating profitability pressure even after the earnings beat. Article Title
• Negative Sentiment: Teleflex’s updated FY2026 EPS guidance of $6.25 to $6.55 came in below the market’s expectation of about $6.73, which could limit enthusiasm despite the quarterly beat. Article Title

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.